The THERAPY Trial: The Randomized, Concurrent Controlled Trial to Assess the Penumbra System's Safety and Effectiveness in the Treatment of Acute Stroke
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 108
- 试验地点
- 4
- 主要终点
- Good Functional Outcome as Defined by a Modified Rankin Score of 0-2
研究概览
简要总结
The purpose of this trial is to assess the safety and effectiveness of the Penumbra System as an adjunctive treatment to intravenous (IV) recombinant human tissue plasminogen activator (rtPA)in patients with acute ischemic stroke from large vessel occlusion in the brain. IV rtPA is the only drug approved for the treatment of acute ischemic stroke but it does not work very well in cases where the stroke is caused by a large vessel occlusion. The hypothesis being tested is to determine if the addition of a treatment by a mechanical thrombectomy device like the Penumbra System can improve the clinical outcome of the patient over just using IV rtPA alone.
详细描述
Current therapies for acute stroke are limited to the intravenous administration of a intravenous (IV) recombinant human tissue plasminogen activator (rtPA) for thrombolysis of the affected cerebral arteries within 3-4.5 hours from symptom onset, and the use of intra-arterial (IA) endovascular mechanical clot retrieval devices within 8 hours from ictus, all of which have limitations as mono therapies. For example, IV rtPA may not be very efficacious in large vessel occlusion and the long term effects of mechanical thrombectomy devices on patient functional outcome is unknown. This is a randomized, concurrent controlled study to assess the safety and effectiveness of the Penumbra System as adjunctive therapy to IV rtPA in the acute intervention of acute ischemic stroke. Patients presenting with symptoms of acute ischemic stroke who have evidence of a large clot burden (clot length > 8mm) in the anterior circulation will be assigned to either IV rtPA therapy alone (0.9mg/kg to a maximum of 90mg) or a combined IV rtPA therapy (0.9mg/kg to a maximum of 90mg) and intra-arterial (IA) adjunctive treatment with the Penumbra System. Each treated patient will be followed and assessed for 3 months after enrollment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •From 18 to 85 years of age
- •Present with symptoms consistent with an acute ischemic stroke and eligible for IV rtPA therapy (patients presenting 3-4.5 hrs from symptom onset are not eligible if they are >80 yrs of age, have a history of stroke and diabetes, anticoagulant use (even if INR is <1.7) and have a NIHSS score >25
- •Evidence of a large vessel occlusion in the anterior circulation with a clot length of 8mm or longer
- •NIH Stroke Scale (NIHSS) score 8 or greater or aphasic at presentation
- •Signed informed consent
排除标准
- •History of stroke in the past 3 months.
- •Females who are pregnant
- •Pre-existing neurological or psychiatric disease that could confound the study results such as a pre-stroke mRS score 1 or greater
- •Known severe allergy to contrast media
- •Uncontrolled hypertension (defined as systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg)
- •CT evidence of the following conditions at randomization:
- •Significant mass effect with midline shift
- •Any acute ischemic changes in >1/3 of the affected middle cerebral artery territory
- •Evidence of intracranial hemorrhage
- •Angiographic evidence of tantem extracranial occlusion or an arterial stenosis proximal to the occlusion that requires treatment prior to thrombus removal. Moderate stenosis not requiring treatment is not an exclusion
- •Angiographic evidence of preexisting arterial injury
- •Rapidly improving neurological status prior to randomization
- •Bilateral stroke
- •Intracranial tumors
- •Known history of cerebral aneurysm or arteriovenous malfunction
- •Known hemorrhagic diathesis, coagulation deficiency, or on anticoagulant therapy with an International Normalized Ratio (INR) of >1.7
- •Baseline platelets <50,000
- •Use of IV heparin in the past 48 hours with PPT >1.5 times the normalized ratio
- •Pre-treatment glucose <50mg/dL or >300mg/dL
- •Life expectancy less than 90 days prior to stroke onset
- •Participation in another clinical investigation that could confound the evaluation of the study device
研究组 & 干预措施
IV rtPA
IV infusion of rtPA at 0.9mg/kg to a maximum of 90mg
干预措施: intravenous (IV) recombinant human tissue plasminogen activator (rtPA) (Drug)
IV rtPA and IA Penumbra System
Dual IV rtPA therapy (0.9mg/kg to a maximum of 90mg) and IA adjunctive treatment with the Penumbra System
干预措施: Penumbra System (Device)
结局指标
主要结局
Good Functional Outcome as Defined by a Modified Rankin Score of 0-2
时间窗: 90 days
The assessor is blinded to patient treatment assignment.
Incidence of All Serious Adverse Events
时间窗: 90 days
A Serious Adverse Event is defined as an event that: 1. Led to death 2. Led to a serious deterioration in the health of the patient that: * Resulted in life-threatening illness or injury * Resulted in permanent impairment of a body structure or a body function * Required in-patient hospitalization or prolongation of existing hospitalization * Resulted in medical or surgical intervention to arrest permanent impairment to body structure or a body function * Led to fetal distress, fetal death or a congenital abnormality or birth defect
次要结局
- Good Clinical Outcome(30 days)
- Incidence of Symptomatic and Asymptomatic Intracranial Hemorrhage(90 days)